| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611
A naturally occurring mutation at amino acid 351 (D351Y) in the human estrogen receptor (ER) can change the pharmacology of antiestrogens. Raloxifene is converted from an antiestrogen to an estrogen, whereas the biological properties of the steroidal pure antiestrogen ICI 182,780 are not affected by the D351Y ER (Levenson, A. S., and Jordan, V. C. Cancer Res., 58: 1872–1875, 1998). We propose an assay system that can be used to classify antiestrogens by determining their ability to up-regulate transforming growth factor 
(TGF-) mRNA in MDA-MB-231 cells stably transfected with either wild-type or D351Y ER. The novel compound EM-800 and its active metabolite, EM-652, have been reported to be p.o. active nonsteroidal pure antiestrogens. Using the D351Y cell line, EM-652 is able to up-regulate TGF- mRNA in a dose-dependent manner and to a similar extent as estradiol, whereas in the wild-type cell line, it acts as an antiestrogen. In addition, the pure antiestrogen ICI 182,780 is capable of inhibiting EM-652-induced TGF- mRNA expression at the D351Y ER. In MCF-7 cells expressing wild-type ER, it has previously been shown that ICI 182,780 decreases ER only at the protein level. EM-652 treatment does not decrease ER protein levels to a similar extent as ICI 182,780 treatment, and, in addition, EM-652 has no effect on ER mRNA levels. In proliferation assays, EM-652 is as effective as raloxifene in inhibiting cell growth. From these studies, we conclude that the reason the pharmacology of EM-652 is similar to that of raloxifene is because they both fit the ER in the same manner, and their biology depends on an interaction of the antiestrogenic side chain with amino acid 351.
This article has been cited by other articles:
|
|
 |
|
  A. M Davis, J. Mao, B. Naz, J. A Kohl, and C. S Rosenfeld Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus J. Mol. Endocrinol., October 1, 2008; 41(4): 205 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Liu, W.-C. Park, D. J. Bentrem, K. P. McKian, A. D. L. Reyes, J. A. Loweth, J. M. Schafer, J. W. Zapf, and V. C. Jordan Structure-Function Relationships of the Raloxifene-Estrogen Receptor-alpha Complex for Regulating Transforming Growth Factor-alpha Expression in Breast Cancer Cells J. Biol. Chem., March 8, 2002; 277(11): 9189 - 9198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Greenberger, T. Annable, K. I. Collins, B. S. Komm, C. R. Lyttle, C. P. Miller, P. G. Satyaswaroop, Y. Zhang, and P. Frost A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats Clin. Cancer Res., October 1, 2001; 7(10): 3166 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schafer, E.-S. Lee, R. C. Dardes, D. Bentrem, R. M. O'Regan, A. De Los Reyes, and V. C. Jordan Analysis of Cross-Resistance of the Selective Estrogen Receptor Modulators Arzoxifene (LY353381) and LY117018 in Tamoxifen-stimulated Breast Cancer Xenografts Clin. Cancer Res., August 1, 2001; 7(8): 2505 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Liu, E.-S. Lee, A. D. L. Reyes, J. W. Zapf, and V. C. Jordan Silencing and Reactivation of the Selective Estrogen Receptor Modulator-Estrogen Receptor {{alpha}} Complex Cancer Res., May 1, 2001; 61(9): 3632 - 3639. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. J. Bentrem, R. C. Dardes, H. Liu, J. MacGregor-Schafer, J. W. Zapf, and V. C. Jordan Molecular Mechanism of Action at Estrogen Receptor {{alpha}} of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen Endocrinology, February 1, 2001; 142(2): 838 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schafer, H. Liu, D. J. Bentrem, J. W. Zapf, and V. C. Jordan Allosteric Silencing of Activating Function 1 in the 4-Hydroxytamoxifen Estrogen Receptor Complex Is Induced by Substituting Glycine for Aspartate at Amino Acid 351 Cancer Res., September 1, 2000; 60(18): 5097 - 5105. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Lippman and P. H. Brown Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819. [Full Text] [PDF]
|
|
|
|
|
|
P. Webb, P. Nguyen, C. Valentine, R. V. Weatherman, T. S. Scanlan, and P. J. Kushner An Antiestrogen-responsive Estrogen Receptor-alpha Mutant (D351Y) Shows Weak AF-2 Activity in the Presence of Tamoxifen J. Biol. Chem., November 22, 2000; 275(48): 37552 - 37558. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
